Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
Adamas Pharmaceuticals (Nasdaq: ADMS) will announce its 2020 Q2 financial results on August 6, 2020, after market close. Following this, management will host a conference call and webcast at 4:30 PM ET to review the results and provide updates on corporate activities. The conference call can be accessed by dialing specific numbers for U.S. and international participants, using Conference ID: 4795503. The webcast will be accessible via Adamas' investor website and remain available for replay until November 5, 2020.
- Scheduled Q2 2020 financial results announcement may provide insights into company performance.
- Management will offer a corporate update during the conference call, which could indicate future strategies.
- None.
EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing (833) 350-1318 for participants in the U.S. or Canada and (236) 738-2277 for international callers. All callers must provide the following Conference ID: 4795503. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay until November 5, 2020.
About Adamas Pharmaceuticals, Inc.
At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.
Contact
Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com
Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com
FAQ
When will Adamas Pharmaceuticals report its Q2 2020 financial results?
What time is the Adamas conference call for Q2 2020 results?
How can I access the Adamas Pharmaceuticals Q2 2020 results webcast?
What is the Conference ID for the Adamas conference call?
Until when will the Adamas webcast be available for replay?
